Abstract 358P
Background
Current treatment guidelines state that resectable early stage NSCLC may be treated with adjuvant therapy in the form of chemotherapy and radiotherapy. For Nonsquamous Non-Small Cell Lung Cancer (NS NSCLC), Epidermal Growth Factor Receptor (EGFR) mutations may be present in up to 60% of cases. In the locally advanced and metastatic settings, EGFR tyrosine kinase inhibitors (TKI) have shown remarkable efficacy. With the basis of EGFR as a driver mutation for carcinogenesis, EGFR TKI treatment has been explored in several studies. However, the role of EGFR TKI in the adjuvant setting remains controversial due to lack of conclusive evidence. The latest treatment guidelines do not favor adjuvant EGFR TKI for EGFR-mutant resected early stage NS-NSCLC. Therefore, this meta-analysis evaluated existing randomized controlled trials (RCTs) for a more precise estimate of the efficacy of adjuvant EGFR TKI and associated lung cancer survival.
Methods
A systematic search of Pubmed, Embase, Cochrane, and clinical trials databases as well as hand search were utilized to identify RCTs investigating adjuvant EGFR TKI treatment in resected NS-NSCLC.
Results
Seven RCTs were included (N=2095), all contain disease free survival (DFS) data. Four trials gave EGFR TKI treatment for 24 months, while one trial provided EGFR TKI treatment for 36 months. Erlotinib, gefitinib, icotinib, and osimertinib were the EGFR TKI used in the RCTs. Treatment with adjuvant EGFR TKI showed statistically significant DFS benefit (HR 0.64, 95% CI[0.50-0.82)], P=0.0005) although with substantial heterogeneity (I2=98%, P<0.00001). This heterogeneity was attributed to trial phase and EGFR TKI generation used. Subgroup analyses were done for trial phase, treatment duration, disease stage, type of EGFR TKI, and toxicity. It was found that use of EGFR TKI gefinitib has statistically significant survival (DFS) advantage (HR 0.56, 95% CI(0.47-0.66), P<0.00001; I2=0%).
Conclusions
Results of this meta-analysis provide preliminary but strong evidence recommending EGFR TKI in the adjuvant setting among EGFR-mutant resected early NS NSCLC by improving DFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session